1
|
McCulloch J, Herrera R, Gutierrez A, Romaguera T, Alvarez D, Kotecha R, Kaiser A, Armas J, Abrams K, Mehta M, Chuong M, Mittauer K. Management of Cardiac Implantable Electronic Devices for Patients Receiving MR-Guided Radiotherapy: 4-Year Single Institution Experience. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Abrams K, Dabus G. Perfusion Scotoma: A Potential Core Underestimation in CT Perfusion in the Delayed Time Window in Patients with Acute Ischemic Stroke. AJNR Am J Neuroradiol 2022; 43:813-816. [PMID: 35618426 DOI: 10.3174/ajnr.a7524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 04/07/2022] [Indexed: 11/07/2022]
Abstract
With the growing rise in utilization of CT perfusion for selecting patients for thrombectomy in acute ischemic stroke from large vessel occlusion, some potential pitfalls are becoming more commonly seen particularly when it comes to estimating the core infarct size on CT perfusion. Ghost infarct core has been described to account for overestimating core infarct size in the early time period (<3 hours). Herein, we describe the phenomenon of underestimating core infarct size on CT perfusion in the later time period (>6 hours), which we have termed perfusion scotoma.
Collapse
|
3
|
Broomfield J, Hill M, Guglieri M, Crowther M, Larkindale J, Godfrey J, Chandler F, Abrams K. DMD/BMD – OUTCOME MEASURES. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Dukes D, Abrams K, Adolphs R, Ahmed ME, Beatty A, Berridge KC, Broomhall S, Brosch T, Campos JJ, Clay Z, Clément F, Cunningham WA, Damasio A, Damasio H, D’Arms J, Davidson JW, de Gelder B, Deonna J, de Sousa R, Ekman P, Ellsworth PC, Fehr E, Fischer A, Foolen A, Frevert U, Grandjean D, Gratch J, Greenberg L, Greenspan P, Gross JJ, Halperin E, Kappas A, Keltner D, Knutson B, Konstan D, Kret ME, LeDoux JE, Lerner JS, Levenson RW, Loewenstein G, Manstead ASR, Maroney TA, Moors A, Niedenthal P, Parkinson B, Pavlidis L, Pelachaud C, Pollak SD, Pourtois G, Roettger-Roessler B, Russell JA, Sauter D, Scarantino A, Scherer KR, Stearns P, Stets JE, Tappolet C, Teroni F, Tsai J, Turner J, Van Reekum C, Vuilleumier P, Wharton T, Sander D. The rise of affectivism. Nat Hum Behav 2021; 5:816-820. [PMID: 34112980 PMCID: PMC8319089 DOI: 10.1038/s41562-021-01130-8] [Citation(s) in RCA: 48] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Research over the past decades has demonstrated the explanatory power of emotions, feelings, motivations, moods, and other affective processes when trying to understand and predict how we think and behave. In this consensus article, we ask: has the increasingly recognized impact of affective phenomena ushered in a new era, the era of affectivism?
Collapse
|
5
|
Agarwal N, Evans R, Abrams K, Dequen-O'Byrne P, McCrea C, Muston D, Gresty C, Ghate S, Fan L, Hettle R, Hawkins N. 622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.881] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
6
|
Abrams K, Carlton J, Chandler F, Crossley E, Crowther M, Ghosh S, Godfrey J, Guglieri M, Hill M, Johnson A, Mumby-Croft J, Powell P, Rowan D, Woodcock F. EP.41Project HERCULES: could international collaboration on value assessment change clinical practice? Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Aujla N, Walker M, Sprigg N, Abrams K, Massey A, Vedhara K. Can illness beliefs, from the common-sense model, prospectively predict adherence to self-management behaviours? A systematic review and meta-analysis. Psychol Health 2016; 31:931-58. [PMID: 26911306 DOI: 10.1080/08870446.2016.1153640] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
OBJECTIVE To determine whether people's beliefs about their illness, conceptualised by the common sense model (CSM), can prospectively predict adherence to self-management behaviours (including, attendance, medication, diet and exercise) in adults with acute and chronic physical illnesses. DESIGN AND MAIN OUTCOME MEASURES Electronic databases were searched in September 2014, for papers specifying the use of the 'CSM' in relation to 'self-management', 'rehabilitation' and 'adherence' in the context of physical illness. Six hundred abstracts emerged. Data from 52 relevant studies were extracted. Twenty-one studies were meta-analysed, using correlation coefficients in random effects models. The remainder were descriptively synthesised. RESULTS The effect sizes for individual illness belief domains and adherence to self-management behaviours ranged from .04 to .13, indicating very weak, predictive relationships. Further analysis revealed that predictive relationships did not differ by the: type of self-management behaviour; acute or chronic illness; or duration of follow-up. CONCLUSION Individual illness belief domains, outlined by the CSM, did not predict adherence to self-management behaviours in adults with physical illnesses. Prospective relationships, controlling for past behaviour, also did not emerge. Other factors, including patients' treatment beliefs and inter-relationships between individual illness beliefs domains, may have influenced potential associations with adherence to self-management behaviours.
Collapse
|
8
|
Slichter SJ, Abrams K, Bailey SL, Pellham E, Gettinger I, Christoffel T, Gaur L, Latchman Y, Nelson K, Bolgiano D. Further studies to evaluate methods of leucoreduction to prevent alloimmune platelet refractoriness and induce tolerance in a dog platelet transfusion model. Vox Sang 2016; 111:62-70. [PMID: 27007858 DOI: 10.1111/vox.12388] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 01/14/2016] [Accepted: 01/14/2016] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Three leucoreduction filters were evaluated - when used alone or combined with centrifuge leucoreduction (C-LR) - to prevent alloimmune platelet refractoriness in a dog platelet transfusion model. MATERIALS AND METHODS Donor platelet-rich plasma (PRP) or buffy coat (BC) platelets were either filter leucoreduced (F-LR) or F-LR/C-LR, (51) Cr radiolabelled and transfused. Weekly transfusions were given for up to 8 weeks or until platelet refractoriness. Recipients who accepted treated transfusions were then given non-leucoreduced (non-LR) platelets to determine whether donor-specific tolerance had been induced. RESULTS Acceptance of F-LR PRP transfusions ranged from 29% to 66%. F-LR/C-LR transfusions prepared from PRP were accepted by 92%, from BC by 63% and from pooled PRP by 75% of recipients (p=NS); overall acceptance rate of F-LR/C-LR transfusions was 83%. Tolerance to subsequent non-LR transfusions occurred in 45% of the F-LR-/C-LR-accepting recipients unrelated to DR-B compatibility between donors and recipients (P = 0·18). CONCLUSION In a dog platelet transfusion model, acceptance of donor platelets required combining F-LR with C-LR as apparently each process removes different immunizing WBCs.
Collapse
|
9
|
Kalabus J, Brogan P, Hofer M, Kuemmerle-Deschner J, Lauwerys B, Speziale A, Laxer R, Sun H, Abrams K, Leon K, Junge G. Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS. Pediatr Rheumatol Online J 2015. [PMCID: PMC4597408 DOI: 10.1186/1546-0096-13-s1-o38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
|
10
|
Brogan P, Hofer M, Kuemmerle-Deschner J, Lauwerys B, Speziale A, Abrams K, Leon K, Wei X, Laxer R. Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab. Pediatr Rheumatol Online J 2015. [PMCID: PMC4597178 DOI: 10.1186/1546-0096-13-s1-p1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
11
|
Horneff G, Ruperto N, Brunner H, Quartier P, Constantin T, Alexeeva E, Kone-Paut I, Marzan K, Wulffraat N, Schneider R, Padeh S, Chasnyk V, Wouters C, Deschner JK, Kallinich T, Lauwerys B, Haddad E, Nasonov E, Trachana M, Vougiouka O, Abrams K, Leon K, Lheritier K, Martini A, Lovell D. Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever. Pediatr Rheumatol Online J 2015. [PMCID: PMC4596972 DOI: 10.1186/1546-0096-13-s1-o83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
12
|
Ruperto N, Brunner H, Quartier P, Constantin T, Alexeeva E, Kone-Paut I, Marzan K, Wulffraat N, Schneider R, Padeh S, Chasnyk V, Wouters C, Kummerle Deschner J, Kallinich T, Lauwerys B, Haddad E, Nasonov E, Trachana M, Vougiouka O, Abrams K, Leon K, Lheritier K, Martini A, Lovell D. FRI0496 Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis with and Without Fever. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
13
|
Kalabus J, Uziel Y, Brogan P, Hofer M, Kuemmerle-Deschner J, Lauwerys B, Speziale A, Laxer R, Lachmann H, Sun H, Abrams K, Leon K, Junge G. SAT0522 Canakinumab Pharmacokinetics in Patients Younger Than 2 Years Old with Cryopyrin Associated Periodic Syndromes. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Uziel Y, Brogan P, Hofer M, Kuemmerle-Deschner J, Lauwerys B, Speziale A, Abrams K, Leon K, Wei X, Laxer R, Lachmann H. THU0536 Efficacy and Post-Vaccination Antibody Titer Data in Children with Caps Aged 28 Days to 4 Years Treated with Canakinumab. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4434] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Gibson CJ, Dixon B, Abrams K. Convergent evolution of health information management and health informatics: a perspective on the future of information professionals in health care. Appl Clin Inform 2015; 6:163-84. [PMID: 25848421 PMCID: PMC4377568 DOI: 10.4338/aci-2014-09-ra-0077] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Accepted: 02/02/2015] [Indexed: 11/23/2022] Open
Abstract
Clearly defined boundaries are disappearing among the activities, sources, and uses of health care data and information managed by health information management (HIM) and health informatics (HI) professionals. Definitions of the professional domains and scopes of practice for HIM and HI are converging with the proliferation of information and communication technologies in health care settings. Convergence is changing both the roles that HIM and HI professionals serve in their organizations as well as the competencies necessary for training future professionals. Many of these changes suggest a blurring of roles and responsibilities with increasingly overlapping curricula, job descriptions, and research agendas. Blurred lines in a highly competitive market create confusion for students and employers. In this essay, we provide some perspective on the changing landscape and suggest a course for the future. First we review the evolving definitions of HIM and HI. We next compare the current domains and competencies, review the characteristics as well as the education and credentialing of both disciplines, and examine areas of convergence. Given the current state, we suggest a path forward to strengthen the contributions HIM and HI professionals and educators make to the evolving health care environment.
Collapse
|
16
|
Boucher R, Abrams K, Lambert PC. Simulating Individual Patient Level Data To Address Treatment Switching When Only Summary Data Are Available. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2014; 17:A579. [PMID: 27201954 DOI: 10.1016/j.jval.2014.08.1955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
17
|
Owen RK, Tincello DG, Bujkiewicz S, Abrams K. Hierarchical Network Meta-Analysis Incorporating Ordering Constraints on Increasing Doses of Interventions - Application to Overactive Bladder Syndrome. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2014; 17:A543. [PMID: 27201751 DOI: 10.1016/j.jval.2014.08.1755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
18
|
Wulffraat NM, Ruperto N, Brunner HI, Oliveira S, Uziel Y, Nistala K, Cimaz R, Ferrandiz MA, Flato B, Gamir M, Kone-Paut I, Gaillez C, Lheritier K, Abrams K, Martini A, Lovell D. Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients. Pediatr Rheumatol Online J 2014. [PMCID: PMC4184294 DOI: 10.1186/1546-0096-12-s1-p68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
|
19
|
Gattorno M, Torene R, Lachmann H, Obici L, Meini A, Tormey V, Caorsi R, Baeriswyl L, Affentranger U, Starck-Schwertz S, Letzkus M, Hartmann N, Abrams K, Nirmala N. Gene expression profiling in understanding the molecular pathogenesis of and response to canakinumab therapy in traps. Pediatr Rheumatol Online J 2014. [PMCID: PMC4190974 DOI: 10.1186/1546-0096-12-s1-p138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
|
20
|
Grom A, Brunner H, Ruperto N, Martini A, Lovell D, Pascual V, Lheritier K, Abrams K, Ilowite N. FRI0528 Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Kuemmerle-Deschner J, Tilson H, Hawkins P, van der Poll T, Walker U, Abrams K, Hoffman H. OP0114 Interim Safety and Efficacy Results of Patients with Cryopyrin-Associated Periodic Syndrome Participating in the β-Confident Registry. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Nirmala N, Torene R, Lachmann H, Obici L, Meini A, Tormey V, Caorsi R, Baeriswyl L, Affentranger U, Starck-Schwertz S, Letzkus M, Hartmann N, Abrams K, Gattorno M. THU0482 Gene Expression Profiling of Whole Blood Samples of TRAPS Patients Shows Insight into the Molecular Pathogenesis of TRAPS and Response to Canakinumab Treatment. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Wulffraat N, Ruperto N, Brunner H, Oliveira S, Uziel Y, Nistala K, Cimaz R, Ferrandiz M, Flato B, Gamir M, Koné-Paut I, Gaillez C, Lheritier K, Abrams K, Martini A, Lovell D. OP0180 Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1215] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
24
|
Brachat A, Grom A, Wulffraat N, Brunner H, Quartier P, Brik R, McCann L, Ozdogan H, Rutkowska-Sak L, Schneider R, Gerloni V, Harel L, Terreri M, Houghton K, Joos R, Kingsbury D, Lopez-Benitez J, Bek S, Schumacher M, Valentin M, Gram H, Abrams K, Martini A, Ruperto N, Lovell D, Nirmala N. OP0007 Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2320] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
25
|
Quartier P, Grom A, Ruperto N, Brunner H, Schikler K, Erguven M, Goffin L, Hofer M, Kallinich T, Marzan K, Gaillez C, Lheritier K, Abrams K, Martini A, Lovell D. OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|